Literature DB >> 24413180

Quantification of total and unbound tranexamic acid in human plasma by ultrafiltration liquid chromatography/tandem mass spectrometry: application to pharmacokinetic analysis.

Xavier Delavenne1, Adeline Montbel2, Sophie Hodin2, Paul Zufferey3, Thierry Basset4.   

Abstract

The present work describes the development and validation of rapid, sensitive and accurate liquid chromatography method, coupled with tandem mass spectrometry detection, for quantification of tranexamic acid in human plasma using isotopically labeled internal standard (IS). A one-step plasma protein precipitation was performed with acetonitrile. UPLC BEH amide column was used for chromatographic separation. Tranexamic acid and IS were detected in multiple reaction monitoring in electrospray positive ionization. The method was linear over the concentration range of 0.8-200mg/L. The intra- and inter-day precision values were below 11.5% and accuracy was better than 9.6%. Total analysis time was reduced to 6min including sample preparation. The present method was successfully applied to pharmacokinetic pilot study in patients undergoing orthopedic surgery. Ultrafiltration allowed confirming the weak binding to plasma proteins and confirming that total plasma TXA concentration is measured by this assay.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Liquid chromatography; Tandem mass spectrometry; Tranexamic acid; Ultrafiltration; antifibrinolytic

Mesh:

Substances:

Year:  2013        PMID: 24413180     DOI: 10.1016/j.jpba.2013.12.005

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

1.  Is tranexamic acid exposure related to blood loss in hip arthroplasty? A pharmacokinetic-pharmacodynamic study.

Authors:  Julien Lanoiselée; Paul J Zufferey; Edouard Ollier; Sophie Hodin; Xavier Delavenne
Journal:  Br J Clin Pharmacol       Date:  2017-11-28       Impact factor: 4.335

2.  TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial.

Authors:  Anne-Sophie Ducloy-Bouthors; Emmanuelle Jeanpierre; Imen Saidi; Anne-Sophie Baptiste; Elodie Simon; Damien Lannoy; Alain Duhamel; Delphine Allorge; Sophie Susen; Benjamin Hennart
Journal:  Trials       Date:  2018-03-01       Impact factor: 2.279

3.  Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial.

Authors:  Anne-Sophie Bouthors; Benjamin Hennart; Emmanuelle Jeanpierre; Anne-Sophie Baptiste; Imen Saidi; Elodie Simon; Damien Lannoy; Alain Duhamel; Delphine Allorge; Sophie Susen
Journal:  Trials       Date:  2018-03-01       Impact factor: 2.279

4.  Acetonitrile Adducts of Tranexamic Acid as Sensitive Ions for Quantification at Residue Levels in Human Plasma by UHPLC-MS/MS.

Authors:  Eduarda M P Silva; Luisa Barreiros; Sara R Fernandes; Paula Sá; João P Prates Ramalho; Marcela A Segundo
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.